Recently, Genetel Pharmaceuticals(Shenzhen)Co.,Ltd. welcomed the good news. According to the relevant provisions of the National "Measures for the Recognition and Management of High-tech Enterprises" and "Guidelines for the Recognition and Management of High-tech Enterprises", Genetel Pharmaceuticals was declared as a state-level high-tech enterprise by Shenzhen Science and Technology Creation Commission from October to 16, 2018. Recently, the company has received the certificate of "National High-tech Enterprises" issued by Shenzhen Science and Technology Innovation Committee, Shenzhen Finance Committee and Shenzhen Tax Bureau of State Administration of Taxation, thus formally entering the ranks of national high-tech enterprises.
Since its establishment on November 3, 2004, Genetel Pharmaceuticals has been developing and innovating continuously in the field of cervical cancer prevention and screening under the concept of "people-oriented, developing science and technology, achieving health". Its products are favored by many enterprises with high quality and high reputation, and its cooperative customers are all over the country. The identification of high-tech enterprises is a comprehensive evaluation and identification of the company's core independent intellectual property rights, transformation ability of scientific and technological achievements, organizational management level of research and development, growth indicators and talent structure, which needs to be screened layer by layer and examined strictly. It shows that Genetel Pharmaceuticals is strongly supported and recognized by the state in innovation and R&D. Meanwhile, it actively promotes the process of independent innovation and R&D.
This evaluation as a national high-tech enterprise will further promote the process of independent innovation and research and development. In the future, Ganglong Biology will continue to uphold the management concept, train high-quality talent team, and provide a fundamental guarantee for independent innovation; at the same time, it will continue to increase investment in scientific research, enrich the enterprise's innovation and development momentum, and further enhance the core competitiveness of enterprises.